Episode 156 - September 26, 2025

0:00-1:02:31

On this week’s episode, Sam Fazeli, Eric Schmidt, PaulMatteis, Brian Skorney, and Brad Loncar dive into what was a positive week for biotech, marked by M&A, offerings, and compelling clinical data, spotlighting Pfizer’s acquisition of Metsera. The conversation shifts to data, starting with UniQure’s three-year Huntington’s disease gene therapy results and Acadia’s Phase 3 results in Prader-Willi syndrome, and the implications for Soleno and Rhythm Therapeutics. Next, the co-hosts overview Stealth Bio’s approval in Barth syndrome and signs of the FDA’s flexibility. Cidara Therapeutics’ influenza prophylaxis antibody and enthusiasm around the Phase 3 results are also discussed. Additionally, positive data from MBX in chronic hypoparathyroidism and PepGen in DM1 further showcase biotech’s rebound, with positive stock reactions. The episode closes with a look at what’s happening at the FDA (some flexibility in rare diseases, CRLs), the latest MAHA press conference – discussion around Tylenol & autism specifically -- and public trust in science. *This episode aired on September 26, 2025.

Publisher

Biotech Hangout

Link

podcasters.spotify.com/pod/show/biotechhangout/episodes/Episode-156---September-26--2025-e38or7u

Published

September 26, 2025

Duration

1h 3m

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

BH

Biotech Hangout

@biotechhangout

#september #lifesciences

The Nile